This page shows the details of why an item matched the keywords from your search.
| Item Type | Name |
|
Concept
|
Indoles
|
|
Academic Article
|
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
|
|
Academic Article
|
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
|
|
Academic Article
|
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
|
|
Academic Article
|
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
|
|
Academic Article
|
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design.
|
|
Academic Article
|
New therapeutic options for renal cell carcinoma.
|
|
Academic Article
|
New targets, therapies, and toxicities: lessons to be learned.
|
|
Academic Article
|
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
|
|
Academic Article
|
Effective therapy for metastatic renal cancer, whither to now.
|
|
Academic Article
|
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
|
|
Academic Article
|
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
|
|
Academic Article
|
Maturing of renal cancer therapeutics.
|
|
Academic Article
|
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.
|
|
Academic Article
|
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
|
|
Academic Article
|
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
|